PharmaNutra S.p.A., a leading pharmaceutical company in the iron-based nutritional supplements sector, listed on the AIM Market Italy, reports important new results and applications for Sucrosomial\u00ae Technology, the patent that has allowed PharmaNutra Group to gain a leadership position in the production of iron-based nutritional supplements.
\nThe official journal of the Italian Internal Medicine Society, \u201cInternal and Emergency Medicine Journal\u201d, has published a study conducted by the group headed by Professor Antonello Pietrangelo, Gastroenterologist and Full Professor of Internal Medicine at Policlinico di Modena Hospital, entitled: \u201cSafety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anaemia\u201d .
\nThis is the first full paper on IBD (Inflammatory Bowel Disease) to demonstrate the efficacy and high tolerability of Sucrosomial Iron\u00ae for treating iron deficiency, a frequent complication of IBD. The use of Sucrosomial\u00ae Iron, supplemented for 12 weeks in a population of 30 subjects with a confirmed diagnosis of Crohn\u2019s disease or ulcerous rectocolitis associated with moderate iron deficiency, significantly improved haemoglobin levels (in 86% of subjects). An improvement was also evident in the progress of the bowel disease during the observation period.
\nThis study thus certifies the value of Sucrosomial\u00ae Iron in an area such as sideropenia in the case of IBD, a condition constantly on the rise in recent years: in Italy alone, according to the scientific society IG-IBD (Italian Inflammatory Bowel Disease Group), 200-250 thousand people are estimated to suffer from inflammatory bowel disease.
\nGermano Tarantino, Scientific Director of PharmaNutra, commented: \u201cThis study confirms and extends the field of application of Sucrosomial\u00ae Iron also in subjects with an iron deficit related to inflammatory bowel disease, increasingly frequent these days. It therefore shows that the Sucrosomial\u00ae Technology developed and patented by PharmaNutra Group enjoys increasing recognition from the scientific community for its efficacy and excellent tolerability, which makes it very useful in all cases of a lack or reduced nutritional intake of iron\u201d.<\/p>\n","protected":false},"excerpt":{"rendered":"
PharmaNutra S.p.A., a leading pharmaceutical company in the iron-based nutritional supplements sector, listed on the AIM Market Italy, reports important new results and applications for Sucrosomial\u00ae Technology, the patent that has allowed PharmaNutra Group to gain a leadership position in the production of iron-based nutritional supplements. The official journal of the Italian Internal Medicine Society, […]<\/p>\n","protected":false},"author":3,"featured_media":2759,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[96,1],"tags":[118,136],"anno_documento":[89],"class_list":["post-10968","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-iron-deficiency","category-senza-categoria","tag-gastroenterology","tag-research-and-technology","anno_documento-2018-en"],"yoast_head":"\n